Related Experiment Video
Updated: Oct 15, 2025

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
[Chinese expert consensus on lipid management in patients with malignancy]
Abstract:
Patients with malignant tumors are often combined with dyslipidemia, and dyslipidemia is associated with both malignant tumor disease and treatment. The expert group of the Integrative Cardio-Oncology Society of China Anti-Cancer Association summarized the incidence rate and characteristics of dyslipidemia in patients with malignant tumors, and the characteristics and mechanisms of dyslipidemia induced by common antineoplastic drugs, stratified the risk of dyslipidemia in antineoplastic drugs, then formulated the principles of dyslipidemia treatment and monitoring. This consensus refers to domestic and aboard research progress, combineds with China's clinical experience to formulate the corresponding prevention and treatment of dyslipidemia. The present consensus provides practical strategies for clinicians in the management of dyslipidemia in malignant tumors and promotes the management of dyslipidemia in malignant tumors in China.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Atherosclerosis III: Management
Angina IV: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:

